| __timestamp | Bio-Techne Corporation | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 15746000 |
| Thursday, January 1, 2015 | 119401000 | 13392000 |
| Friday, January 1, 2016 | 140879000 | 9290000 |
| Sunday, January 1, 2017 | 199243000 | 7672000 |
| Monday, January 1, 2018 | 240636000 | 15293000 |
| Tuesday, January 1, 2019 | 264359000 | 22648000 |
| Wednesday, January 1, 2020 | 260583000 | 21864000 |
| Friday, January 1, 2021 | 324951000 | 37318000 |
| Saturday, January 1, 2022 | 372766000 | 48130000 |
| Sunday, January 1, 2023 | 378378000 | 108146000 |
| Monday, January 1, 2024 | 396826000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Bio-Techne Corporation and Madrigal Pharmaceuticals, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, Bio-Techne's SG&A expenses have surged by over 550%, reflecting their aggressive expansion and investment strategies. In contrast, Madrigal Pharmaceuticals has shown a more conservative approach, with their SG&A costs increasing by approximately 590% during the same period, albeit from a much smaller base.
Bio-Techne's expenses peaked in 2024, while Madrigal's data for that year remains unavailable, leaving room for speculation about their current financial strategies. This comparison highlights the diverse approaches companies can take in managing operational costs, each with its own set of challenges and opportunities.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Biogen Inc. and Bio-Techne Corporation
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Vericel Corporation
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?